Health Care/Hospital
Hankyung.com introduces: Unmissable BFCM Deal on Amazon: Get EXTREME DUAL ARGININE PLUS, Free Shipping, and Subscribe & Save Options!
https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.jpg
2024-11-19 21:00
1411
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...
2024-11-19 20:30
1314
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development
BEIJING, Nov. 19, 2024 /PRNewswire/ -- With the support of the RiDYMO® platform, we are able to comprehensively explore various potential targets in drug development, including protein-protein interactions, kinases, GPCRs, ion channels, and transcription factors. Polo-like kinase 1 (PLK1) is a h...
2024-11-19 16:00
1111
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects
TAIPEI, Nov. 19, 2024 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In July 2023, the U.S. Food & Drug Administration (FDA) accepted T...
2024-11-19 14:08
1251
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
* SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using analpha-particle emitting radioisotope, actinium-225, for potential cancer treatments * The two sides aim to submit an Investigatio...
2024-11-19 08:00
1722
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Convergence 2024
* 78-Week results from Phase III randomized controlled trial (RCT) including switching data from reference denosumab to CT-P41 (biosimilar candidate of denosumab) demonstrate comparable efficacy and safety results; Results support the therapeutic equivalence of CT-P41 and reference denosumab in...
2024-11-19 02:15
1462
WAT Medical Continues Support for Red Cross and Veterans Association
VANCOUVER, BC, Nov. 18, 2024 /PRNewswire/ -- WAT Medical Enterprise Ltd. proudly reaffirms its commitment to community support by donating to the American Red Cross and the American Veterans Association. These donations are part of the company's pledge to contribute a portion of the proceeds from...
2024-11-18 22:30
1025
C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital
CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion of its Series A+ financing round exceeding$100 million. This round ...
2024-11-18 22:00
1847
Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC
Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer driver mutations SEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, ...
2024-11-18 22:00
1611
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
* Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed$900M with tiered single digit sal...
2024-11-18 21:50
1375
Akeso Biopharma to Attend Jefferies London Healthcare Conference and Morgan Stanley 23rd Asia Pacific Summit
HONG KONG, Nov. 18, 2024 /PRNewswire/ -- Akeso Biopharma (9926. HK) ("Akeso" or the "Company") is pleased to announce thatDr. Michelle Xia, the company's founder, chairwoman, president, and CEO, will attend Morgan Stanley's 23rd Asia Pacific Summit.Dr. Bing C. Wang, the company's chief financial ...
2024-11-18 21:16
1297
WELLlife COVID-19/Influenza A&B Home Test on Sale for Black Friday and Cyber Monday
BOLINGBROOK, Ill. , Nov. 18, 2024 /PRNewswire/ -- Stock up your family's medicine cabinet this Black Friday and Cyber Monday. WELLlife, a leading innovator in medical diagnostic and testing solutions, is increasing accessibility to respiratory illness testing in preparation for the year-end holi...
2024-11-18 21:00
1049
Bestqool Pro Advanced Series: Revolutionizing Red Light Therapy This Black Friday
NEW YORK, Nov. 18, 2024 /PRNewswire/ -- With winter just around the
corner, Bestqool is proud to offer a head start on wellness with their advanced
Pro Series
2024-11-18 21:00
1203
TenNor Announces Positive Topline Results from Rifasutenizol Phase III Trial for H. pylori Infection
SUZHOU, China, Nov 18, 2024 /PRNewswire/ -- TenNor Therapeutics, a clinical-stage company dedicated to developing novel therapies to address unmet needs in infectious diseases, announced today the successful completion of a phase III clinical trial of rifasutenizol (TNP-2198) for the treatment of...
2024-11-18 19:00
1242
FDA Grants Breakthrough Therapy Designation to Huahui Health's Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection
BEIJING, Nov. 18, 2024 /PRNewswire/ -- Huahui Health, a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis, hepatology, and oncology, today announced that its investigational hepatitis D and B drug candidate, Libevitug (HH-00...
2024-11-18 18:40
1085
SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors
TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd.
2024-11-18 08:00
1298
DermRays Black Friday Event Offers Year's Biggest Savings and Industry Recognition
PLEASANTON, Calif., Nov. 16, 2024 /PRNewswire/ -- This Black Friday, DermRays is excited to announce its most significant sale of the year, offering$130 off sitewide fromNovember 16-30th, 2024. With this limited-time discount, customers can experience the brand's advanced home laser hair removal ...
2024-11-16 21:00
1626
World-Class Scientists Gather at Tencent 2024 WE Summit in Chengdu to Share Cutting-Edge Discoveries
Five eminent speakers, including Nobel laureates and the top Chinese physicist Qi-Kun Xue, share groundbreaking insights at theTencent WE Summit in Chengdu. SHENZHEN, China, Nov. 15, 2024 /PRNewswire/ -- On November 3, the 12th Annual Tencent WE Summit took place at the Chengdu Science Fiction Mu...
2024-11-15 22:57
1852
Neurophet Appoints CTO Donghyeon Kim as Co-CEO, Joining Jake Junkil Been in Dual Leadership to Drive Global Growth
- Donghyeon Kim, Co-Founder and CTO of Neurophet, to Take On Dual Role as CEO, Heading Technology and Company Leadership - Aims to Strategically Expand Business and Management Functions for Establishing a Strong Presence in Global Markets SEOUL, South Korea, Nov. 15, 2024 /PRNewswire/ -- Neuroph...
2024-11-15 22:00
1708
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease
* IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program * ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) * The planned clinical ...
2024-11-15 20:00
1353
Week's Top Stories
Most Reposted
Star-Studded Sponsor Line-up Takes Centre Court at the Singapore Tennis Open 2025
[Picked up by 293 media titles]
2025-01-28 10:49
Sephora Unveils Its First Film, "Beauty & Belonging" Celebrating Diversity and Authenticity
[Picked up by 288 media titles]
2025-01-24 08:00
Dahua Technology Joins Hands with WWF to Expand Sustainability Efforts Globally
[Picked up by 270 media titles]
2025-01-24 12:15
HZICC: Linping Manufacturing Goes Global to Promote City Brand
[Picked up by 266 media titles]
2025-01-24 22:59Sushui Tech to Launch New DMFC Products at Smart Energy Week, Tokyo 2025
[Picked up by 260 media titles]
2025-01-28 09:53
Most Read
BRI UMKM EXPO(RT) 2025 Returns: Showcasing Local Products to the World
2025-01-25 15:38
8596
U Power Announces Pricing of $5.0 Million Registered Direct Offering
2025-01-24 22:18
5729
Industrial legacy boosts tourism development in Shenyang
2025-01-24 22:18
5119